Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 7:7:43238.
doi: 10.1038/srep43238.

A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains

Affiliations

A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains

G Craig Wood et al. Sci Rep. .

Abstract

Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of conditions that include steatohepatitis and fibrosis that are thought to emanate from hepatic steatosis. Few robust biomarkers or diagnostic tests have been developed for hepatic steatosis in the setting of obesity. We have developed a multi-component classifier for hepatic steatosis comprised of phenotypic, genomic, and proteomic variables using data from 576 adults with extreme obesity who underwent bariatric surgery and intra-operative liver biopsy. Using a 443 patient training set, protein biomarker discovery was performed using the highly multiplexed SOMAscan® proteomic assay, a set of 19 clinical variables, and the steatosis predisposing PNPLA3 rs738409 single nucleotide polymorphism genotype status. The most stable markers were selected using a stability selection algorithm with a L1-regularized logistic regression kernel and were then fitted with logistic regression models to classify steatosis, that were then tested against a 133 sample blinded verification set. The highest area under the ROC curve (AUC) for steatosis of PNPLA3 rs738409 genotype, 8 proteins, or 19 phenotypic variables was 0.913, whereas the final classifier that included variables from all three domains had an AUC of 0.935. These data indicate that multi-domain modeling has better predictive power than comprehensive analysis of variables from a single domain.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interests.

Figures

Figure 1
Figure 1. Plot of unadjusted p-values for association between each protein expression and presence of any steatosis.
The labeled proteins were those selected for inclusion in final model.
Figure 2
Figure 2. ROC curves for Discovery Model*.
*Note that PNPLA3 was included as the number of alleles (0, 1, 2) and was treated as an ordinal variable. Those with unknown PNPLA3 status were included in the model by using a common missing data strategy (i.e. treating them as a separate subgroup).
Figure 3
Figure 3. ROC curves for Validation model.

Similar articles

Cited by

References

    1. Neuschwander-Tetri B. A. & Caldwell S. H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37, 1202–1219, doi: 10.1053/jhep.2003.50193 (2003). - DOI - PubMed
    1. Chalasani N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55, 2005–2023, doi: 10.1002/hep.25762 (2012). - DOI - PubMed
    1. Matteoni C. A. et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413–1419 (1999). - PubMed
    1. Rafiq N. et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 7, 234–238, doi: 10.1016/j.cgh.2008.11.005 (2009). - DOI - PubMed
    1. McCullough A. J. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clinics in liver disease 8, 521–533, viii, doi: 10.1016/j.cld.2004.04.004 (2004). - DOI - PubMed

Publication types